API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Under the agreement, Trevena awarded Premier to take advantage of special pricing for Olinvyk. Olinvyk contains oliceridine, an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Trevena
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 04, 2023
Details:
The funding was triggered by the first commercial sale of OLINVYK (oliceridine), contains oliceridine, an opioid, which is a Schedule II controlled substance, indicated in adults for the management of acute pain severe, in China by Jiangsu Nhwa.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CBC Group
Deal Size: $40.0 million Upfront Cash: $15.0 million
Deal Type: Financing September 06, 2023
Details:
Under the license agreement, Nhwa granted a license to develop, manufacture, and commercialize Olinvyk (oliceridine), an opioid medication that is used for the treatment of moderate to severe acute pain in adults, in China.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jiangsu Nhwa Pharmaceutical
Deal Size: $5.5 million Upfront Cash: $2.5 million
Deal Type: Licensing Agreement May 31, 2023
Details:
Olinvyk (oliceridine), recently approved in China, is an opioid, schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
Olinvyk (oliceridine), an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
OLINVYK (oliceridine) study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
OLINVYK contains oliceridine, an opioid, which is Schedule II controlled substance with high potential for abuse similar, indicated in adults for management of acute pain severe enough to require an intravenous opioid analgesic and whom alternative treatments are inadequate.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
OLINVYK (oliceridine) injection showed a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
The R-Bridge Financing will be repaid through assignment to R-Bridge of all royalties from the Company’s license with its partner in China, Jiangsu Nhwa Pharmaceutical (Nhwa) and through a 4% net revenue interest in the Company’s US net sales of OLINVYK.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: R-Bridge Healthcare Fund
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 18, 2022
Details:
OLINVYK (oliceridine) injection, is a new chemical entity approved by FDA indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Details:
The R-Bridge Financing will be repaid through assignment to R-Bridge of all royalties from the Company’s license with its partner in China, Jiangsu Nhwa Pharmaceutical (Nhwa) and through a 4% net revenue interest in the Company’s US net sales of OLINVYK.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: R-Bridge Healthcare Fund
Deal Size: $40.0 million Upfront Cash: $15.0 million
Deal Type: Financing March 31, 2022
Details:
Alcami is providing commercial manufacturing services for Trevena's newly approved OLINVYK. OLINVYK (oliceridine) injection is an opioid approved in adults for the management of acute pain severe enough to require an intravenous opioid analgesic.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Trevena
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 26, 2020
Details:
U.S. Food and Drug Administration (FDA) has approved OLINVYK in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
The company’s partner, Jiangsu Nhwa, has been approved by the Chinese National Medical Products Administration (NMPA) to initiate clinical trials for IV oliceridine, Trevena’s lead investigational asset for the management of moderate-to-severe acute pain.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
Overview of clinical and nonclinical data to date for oliceridine; includes efficacy data in hard- and soft- tissue surgeries, safety / tolerability data in high-risk patients .
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020